“…DESIGN, SETTING, AND PARTICIPANTS: This prognostic study analyzed data of participants in the OPERAM (Optimising Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older People) trial, which was conducted between December 1, 2016, and October 31, 2018, in surgical and nonsurgical departments of 4 university-based hospitals in Louvain, Belgium; Utrecht, the Netherlands; Cork, Republic of Ireland; and Bern, Switzerland. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DESIGN, SETTING, AND PARTICIPANTS: This prospective, population-based cohort study was embedded in the Generation R Study, Rotterdam, the Netherlands. The Generation R Study was launched in 2002, with follow-up ongoing. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…TRIAL REGISTRATION: Netherlands Trial Registry Identifier: NL7995…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Phylogenetic analysis revealed that PJ201984 clustered together with multiple CV-A12 strains isolated in China and the Netherlands during 2013–2018, as compared to another cluster consisting of CV-A12 strains in China and France during 2009–2015. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: This laboratory study investigates the enhanced monofocal intraocular lens (L-333) and the monofocal counterpart (L-313) IOL by Teleon Surgical, Spankeren, Netherlands on the optical bench, using OptiSpheric IOL PRO2 (Trioptics, Germany) in order to assess the optical quality according to ISO 11979 with ISO-2 Cornea. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…SPEAKERS/PANELLISTS: Victoria Palmi European Medicines Agency, Amsterdam, Netherlands Mariana Roldão Santos WHO, Geneve, Switzerland Richard Pilsudski Sanofi, Paris, France…”
Enlace del recurso
Enlace del recurso

“…SETTING: Routinely collected health data from contributing datasets in France, Germany, the Netherlands, Spain, the UK, and the US. PARTICIPANTS: Adults (age ≥18 years) registered at any contributing database and who received at least one dose of a covid-19 vaccine (ChAdOx1-S (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), or Ad26.COV2.S (Janssen/Johnson & Johnson)), from December 2020 to mid-2021. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This study aims to assess the factors associated with polypharmacy and the high risk of medication-related problems among community-dwelling older people in the Netherlands, Greece, Croatia, Spain, United Kingdom. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…TRIAL REGISTRATION: Netherlands Trial Register NL9378; https://trialsearch.who.int/Trial2.aspx?…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DESIGN, SETTING, AND PARTICIPANTS: This multicenter prospective prognostic study was performed in the general oncology inpatient and outpatient clinics of 6 hospitals in the Netherlands. A total of 867 patients were enrolled between June 2 and November 22, 2017, and followed up for 1 year. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: sNfL, sGFAP (both singe-molecule array technology) and sCNTN1 (Luminex) were measured in serum samples of 288 PwMS and 125 healthy controls (HCs) of the Project Y cohort, a population-based cross-sectional study of PwMS born in the Netherlands in 1966 and age-matched HC. RESULTS: sNfL (9.83 pg/mL [interquartile range {IQR}: 7.8–12.0]) and sGFAP (63.7 pg/mL [IQR: 48.5–84.5]) were higher in PwMS compared with HC (sNfL: 8.8 pg/mL [IQR: 7.0–10.5]; sGFAP: 51.7 pg/mL [IQR: 40.1–68.3]) (p < 0.001), whereas contactin-1 (7,461.3 pg/mL [IQR: 5,951.8–9,488.6]) did not significantly differ between PwMS compared with HC (7,891.2 pg/mL [IQR: 6,120.0–10,265.8]) (p = 0.068). sNfL and sGFAP levels were 1.2-fold higher in secondary progressive patients (SPMS) compared with relapsing remitting patients (p = 0.009 and p = 0.043). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…TRIAL REGISTRATION: Netherlands Trial Register NL9226; https://trialsearch.who.int/Trial2.aspx?…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…SPEAKERS/PANELLISTS: Peter Groenewegen NIVEL, Utrecht, Netherlands Ilmo Keskimäki Finnish Institute for Health and Welfare, Helsinki, Finland Alastair Leyland University of Glasgow, Glasgow, UK Ellen Nolte LSHTM, London, UK…”
Enlace del recurso
Enlace del recurso

“…The rest of the studies were from China (n = 1), France (n = 1), Germany (n = 1), Italy (n = 1), the Netherlands (n = 1), Pakistan (n = 1), Switzerland (n = 1), Saudi Arabia (n = 1) and Ukraine (n = 1). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…STUDY DESIGN: We conducted a retrospective cohort study of women determined to have a cesarean scar pregnancy from 2010 to 2021 at a tertiary referral center, the Amsterdam University Medical Center, in the Netherlands. Outcomes of the following management strategies were compared: expectant management, methotrexate, curettage with temporary cervical cerclage, or a laparoscopic niche resection. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DESIGN, SETTING, AND PARTICIPANTS: The Frontotemporal Dementia Incidence European Research Study (FRONTIERS) was a retrospective cohort study conducted from June 1, 2018, to May 31, 2019, using a population-based registry from 13 tertiary FTLD research clinics from the UK, the Netherlands, Finland, Sweden, Spain, Bulgaria, Serbia, Germany, and Italy and including all new FTLD-associated cases during the study period, with a combined catchment population of 11 023 643 person-years. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DESIGN, SETTING, AND PARTICIPANTS: A nested case-control study examined 5-year HL survivors at 5 hospital centers in the Netherlands. Participants had been diagnosed with HL in 1964 to 2000, when they were 15 to 50 years of age, and were followed for a median of approximately 26 years. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: A first retrospective descriptive study was conducted at the Leiden University Medical Center in the Netherlands. Patients who sent at least one eConsult to a hospital pharmacist between March 2017 and December 2021 were included. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: Participants were recruited from socially disadvantaged areas around participating study supermarkets (n = 12 supermarkets) across the Netherlands, aged 30–80 years, and regular shoppers of the participating supermarkets. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…PARTICIPANTS: The trial will be conducted in the Netherlands. A target of 20,000 subjects will be enrolled. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso